Emerging evidence indicates that factors from the tumor microenvironment including HGF play a significant role in the regulation of UM cells and their acquired resistance mechanisms to targeted therapies such as MEK inhibition [17,18]. The gene discussed is MAP2K7; the disease is neoplasm.